|
|
 |
|
Viewing report
|
|
|
|
The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
GBI Research, May 2010, Pages: 138
“The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 – Strategies to Counter Generic Erosion in Key Markets', provides in-depth analysis of the unmet needs, drivers and barriers that impact the global ophthalmology therapeutics market. The report analyzes the ophthalmology markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes:
- Annualized market data for the ophthalmology market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including glaucoma, macular degeneration, macular edema and allergic conjunctivitis.
- Analysis of the ophthalmology market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom),
Germany, France, Italy, Spain and Japan.
- Market characterization of the ophthalmology market including market size, the annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in the various phases of drug development.
- Competitive benchmarking of leading companies such as Pfizer, Allergan, Inc., Alcon, Inc., Novartis AG, Merck & Co Inc and Roche.
- Key M&A activities that have taken place in 2009 and the licensing agreements in the 2008-2009 global ophthalmology market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market
Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin
Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs
Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment
Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market
Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
Specialty Pharmaceutical Industry - 2011 Yearbook
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
|
|
|
|
